文献速递心脑血管急症重症综合管理与镇静镇痛

心脏骤停后神经预后评估的影像学检查:系统评价与Meta分析

Imaging for Neuroprognostication After Cardiac Arrest: Systematic Review and Meta-analysis.
PubMed 文献 · Neurocrit Care · 2020-01-01
一句话结论心脏骤停后昏迷患者中,CT灰白质比值降低及MRI弥散加权成像或弥散加权成像联合FLAIR可辅助预测早期神经预后不良。

该系统评价与Meta分析检索MEDLINE(建库至2018年8月),纳入44项观察性队列研究或随机对照试验,评估成人(16岁及以上)心脏骤停幸存者脑CT或MRI对神经预后或死亡的预测准确性。结果发现CT灰白质比值降低(20项研究)预测神经预后不良的敏感度0.44、特异度0.97、阳性似然比13.8;MRI弥散加权成像(16项研究)敏感度0.77、特异度0.92、阳性似然比9.2;弥散加权成像联合FLAIR(4项研究)敏感度0.70、特异度0.95、阳性似然比13.4。影像学检查与神经功能评估相对于心脏骤停的时间点存在显著异质性。

要点

  • CT灰白质比值降低预测神经预后不良特异度0.97(95%CI 0.93-0.99),阳性似然比13.8(95%CI 6.9-27.7),敏感度仅0.44(95%CI 0.29-0.60)。
  • MRI弥散加权成像预测神经预后不良敏感度0.77(95%CI 0.65-0.85)、特异度0.92(95%CI 0.85-0.96),阳性似然比9.2(95%CI 5.2-16.4)。
  • MRI弥散加权成像联合FLAIR预测神经预后不良敏感度0.70(95%CI 0.43-0.88)、特异度0.95(95%CI 0.79-0.99),阳性似然比13.4(95%CI 3.5-51.2)。
  • 影像学检查与神经功能评估相对于心脏骤停的时间点存在显著异质性,解读结果时需结合检查时机。
  • CT灰白质比值降低、MRI弥散加权成像或弥散加权成像联合FLAIR是预测心脏骤停后早期神经预后不良的有用辅助手段。

适用人群与场景

  • 成人(16岁或以上)心脏骤停后昏迷幸存者,评估脑CT或MRI对神经预后或死亡的预测准确性。

研究设计与关键结果

  • 系统评价与Meta分析,纳入44项研究(脑CT 24项、MRI 21项),共4008例患者(每项研究9-398例)。
  • CT灰白质比值降低(20项研究)预测神经预后不良:敏感度0.44(95%CI 0.29-0.60)、特异度0.97(95%CI 0.93-0.99)、阳性似然比13.8(95%CI 6.9-27.7)。
  • MRI弥散加权成像(16项研究)预测神经预后不良:敏感度0.77(95%CI 0.65-0.85)、特异度0.92(95%CI 0.85-0.96)、阳性似然比9.2(95%CI 5.2-16.4)。
  • MRI弥散加权成像联合FLAIR(4项研究)预测神经预后不良:敏感度0.70(95%CI 0.43-0.88)、特异度0.95(95%CI 0.79-0.99)、阳性似然比13.4(95%CI 3.5-51.2)。
  • 影像学检查与神经功能评估相对于心脏骤停的时间点存在显著异质性。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入观察性队列研究或随机对照试验。
  • 研究质量采用诊断准确性研究质量评价工具第2版(QUADAS-2)评估。
  • 局限:影像学检查与神经功能评估相对于心脏骤停的时间点存在显著异质性。

对床旁实践的改变

  • CT灰白质比值降低、MRI弥散加权成像或弥散加权成像联合FLAIR可作为预测心脏骤停后早期神经预后不良的辅助手段。
  • 解读影像学预后预测结果时需考虑检查与评估相对于心脏骤停的时间点存在显著异质性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Predicting neurological outcome in comatose survivors of cardiac arrest relies on clinical findings, radiological and neurophysiological test results. To evaluate the predictive accuracy of brain computed tomography (CT) and magnetic resonance imaging (MRI) for prognostication of neurological outcomes after cardiac arrest.

METHODS: We searched MEDLINE (database inception to August 2018) and included all observational cohort studies or randomized controlled trials including adult (16 years or older) survivors of cardiac arrest which evaluated the diagnostic accuracy of CT or MRI for predicting neurologic outcome or mortality. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. All review stages were conducted independently by 2 reviewers, and where possible data were pooled using bivariate meta-analysis. The main outcome was to evaluate the of accuracy of CT and MRI in neuroprognostication of patients after cardiac arrest.

RESULTS: We included 44 studies that examined brain CT (n = 24) or MRI (n = 21) in 4008 (n per study, 9-398) patients. Decreased grey to white matter ratio on CT (20 studies) was useful for predicting poor neurological outcome (sensitivity 0.44, 95% CI 0.29-0.60; specificity 0.97, 95% CI 0.93-0.99; positive likelihood ratio [LR+] 13.8, 95% CI 6.9-27.7). Similarly, diffusion-weighted imaging (DWI) on MRI (16 studies; sensitivity 0.77, 95% CI 0.65-0.85; specificity 0.92, 95% CI 0.85-0.96; LR+ 9.2, 95% CI 5.2-16.4) and DWI and fluid-attenuated inversion recovery (FLAIR) MRI (4 studies, sensitivity 0.70, 95% CI 0.43-0.88; specificity 0.95, 95% CI 0.79-0.99; LR+ 13.4, 95% CI 3.5-51.2) were useful for predicting poor neurological outcomes. We found marked heterogeneity in timing of radiological examinations and neurological assessments relative to the cardiac arrest.

CONCLUSION: Decreased grey to white matter ratio on CT and DWI or DWI and FLAIR on MRI are useful adjuncts for predicting poor early neurological outcome after cardiac arrest.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Lopez Soto C, Dragoi L, Heyn CC, et al. Imaging for Neuroprognostication After Cardiac Arrest: Systematic Review and Meta-analysis. Neurocrit Care. 2020. PMID: 31549351. doi:10.1007/s12028-019-00842-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。